Infant Anaphylaxis Often Resolves After a Single Epinephrine Dose
Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
Publisher: HCP Live
Q&A: Anaphylaxis Recognition and Epinephrine Use, With Jay Lieberman, MD
Anaphylaxis recognition criteria have not been updated to reflect infant-specific presentations, even as newer international definitions already incorporate them.
Stock Epinephrine Could Close Anaphylaxis Care Gap, With Jay Lieberman, MD
Reframing when caregivers reach for epinephrine and expanding stock epinephrine access could meaningfully reduce delayed treatment in infants and toddlers with anaphylaxis, according to Jay Lieberman, MD, professor at the University of Tennessee Health Science Center and program director of the Allergy/Immunology Fellowship Program at Le Bonheur Children’s Hospital.
Age-Specific Criteria Improve Anaphylaxis Detection in Infants
New reviews outline barriers to epinephrine use and support age-specific anaphylaxis recognition criteria in infants and toddlers, says Jay Lieberman, MD.
Unmet Needs and Challenges in Allergy Management
This 4-part special report examines persistent unmet needs and evolving best practices in anaphylaxis care, drawing on expert discussions from HCPLive, Contemporary Pediatrics, and Patient Care.
FDA Issues CRL to Dibutepinephrine (Anaphylm) Sublingual Film for Type 1 Allergic Reactions
The CRL cited deficiencies limited to packaging and administration, with resubmission expected as early as Q3 2026.
Phase 2 Trial of ILYX-002 Shows Improved Conjunctival Staining in DED, with Penny Asbell, MD, MBA
Investigative topical immunomodulator ILYX-002 has proven its efficacy in treating moderate-to-severe dry eye disease (DED) by achieving its primary endpoint of total conjunctival staining in the recent ILYX-002-201 phase 2 trial.
Discussing Dose Flexibility in Adult Atopic Dermatitis, with Tejesh Patel, MD
At the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee, the HCPLive editorial team sat down with Tejesh Patel, MD/MBBS, about his portion of the session at RAD titled ‘Dose Flexibility in Adult Atopic Dermatitis.’